NCT02148718View on ClinicalTrials.gov

Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease

PHASE4CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

January 31, 2017

Conditions

Moderate to Severe Crohn's Disease

Interventions

BIOLOGICAL

adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous injection

Sponsors

Lead Sponsor

Collaborators (1)

Laboratorio Echevarne

All Listed Sponsors

collaborator

Laboratorio Echevarne

INDUSTRY

collaborator

Pivotal S.L.

INDUSTRY

lead

AbbVie

INDUSTRY